HCW Biologics prices $1.6M private placement of units with pre-funded and common warrants

HCW Biologics Inc.

Issued 618,682 units at $2.585 per unit; includes 218,682 shares and 400,000 pre-funded warrants.
Gross proceeds of $1.6M; net proceeds for clinical trials (HCW9302, HCW11-018b, HCW11-040) and working capital.
CEO Hing C. Wong, Chairman Scott Garrett, and SVP Lee Flowers participated on same terms as other investors.
Common warrants for up to 618,682 shares require stockholder approval under Nasdaq Rule 5635(d).
Pre-funded warrants exercisable at $0.0001; common warrants at $2.585, expire 5.5 years from issuance.

item 1.01 item 3.02 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.